Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 11/20 | 0.67 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.62 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 1/20 | 0.51 |
| ▸ | AKT2 | P31751 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6522958 | 1.00 | GSK3B (0.67) | GSK3BNOX4LRRK2PDPK1JAK3 | |
| SCHEMBL6524644 | 0.93 | GSK3B (0.57) | GSK3BNOX4LRRK2PDPK1JAK3 | |
| SCHEMBL6524639 | 0.93 | GSK3B (0.57) | GSK3BNOX4LRRK2PDPK1JAK3 | |
| SCHEMBL12848341 | 0.92 | GSK3B (0.67) | GSK3BNOX4LRRK2PDPK1JAK3 | |
| SCHEMBL6523692 | 0.88 | GSK3B (0.51) | GSK3BNOX4LRRK2PDPK1PAK1 | |
| SCHEMBL6523663 | 0.88 | GSK3B (0.51) | GSK3BNOX4LRRK2PDPK1PAK1 | |
| SCHEMBL12795021 | 0.85 | GSK3B (0.57) | GSK3BNOX4LRRK2PDPK1JAK3 | |
| SCHEMBL6524933 | 0.84 | PDPK1 (0.57) | GSK3BNOX4LRRK2PDPK1APP | |
| SCHEMBL6524929 | 0.84 | PDPK1 (0.57) | GSK3BNOX4LRRK2PDPK1APP | |
| SCHEMBL6522169 | 0.82 | PDPK1 (0.46) | GSK3BNOX4LRRK2PDPK1APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765748-B2 | Indazolyl, benzimidazolyl, benzotriazolyl substituted indolinone derivatives as kinase inhibitors useful in the treatment of cancer | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | UNIVERSITY HEALTH NETWORK | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065702-A1 | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL SUBSTITUTED INDOLINONE DERIVATIVES AS KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | TNNI3K, ABL1, TK1 | GSK3B 621/4885NOX4 3628/4885LRRK2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.